EMA has recommended that the use of Yondelis (trabectedin) in treating ovarian cancer remain unchanged following a review of a study that investigated... Array

Content Original Link:

https://www.ema.europa.eu/en/news/authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data